Embecta (NASDAQ:EMBC) Director Milton Mayo Morris Sells 6,293 Shares

Posted by Francis Steltz on Sep 8th, 2026

Embecta Corp. (NASDAQ:EMBC – Get Free Report) Director Milton Mayo Morris sold 6,293 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $5.88, for a total transaction of $37,002.84. Following the completion of the sale, the director directly owned 53,828 shares in the company, valued at $316,508.64. This represents a 10.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Embecta Price Performance

EMBC stock traded down $0.25 on Tuesday, hitting $5.55. 1,361,544 shares of the company were exchanged, compared to its average volume of 1,580,282. Embecta Corp. has a twelve month low of $2.77 and a twelve month high of $15.55. The business’s fifty day moving average is $4.18 and its two-hundred day moving average is $5.80. The stock has a market capitalization of $314.46 million, a price-to-earnings ratio of 3.75 and a beta of 0.86.

Embecta (NASDAQ:EMBC – Get Free Report) last posted its quarterly earnings results on Friday, August 7th. The company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.29. Embecta had a net margin of 8.59% and a negative return on equity of 19.25%. The company had revenue of $271.70 million for the quarter, compared to the consensus estimate of $254.53 million. During the same quarter last year, the firm posted $1.12 earnings per share. Embecta’s revenue was down 8.1% on a year-over-year basis. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. Equities research analysts expect that Embecta Corp. will post 1.84 earnings per share for the current year.

Embecta Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Thursday, August 27th will be issued a $0.01 dividend. The ex-dividend date is Thursday, August 27th. This represents a $0.04 dividend on an annualized basis and a yield of 0.7%. Embecta’s dividend payout ratio (DPR) is presently 2.70%.

Hedge Funds Weigh In On Embecta

Hedge funds and other institutional investors have recently made changes to their positions in the business. Royal Bank of Canada increased its holdings in Embecta by 38.3% in the 1st quarter. Royal Bank of Canada now owns 18,201 shares of the company’s stock valued at $232,000 after purchasing an additional 5,036 shares in the last quarter. AQR Capital Management LLC lifted its stake in shares of Embecta by 3.7% during the first quarter. AQR Capital Management LLC now owns 225,641 shares of the company’s stock worth $2,738,000 after purchasing an additional 8,109 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Embecta by 2.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,323 shares of the company’s stock worth $629,000 after purchasing an additional 1,159 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Embecta by 4.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 172,173 shares of the company’s stock worth $2,195,000 after buying an additional 7,894 shares during the period. Finally, Jane Street Group LLC boosted its position in shares of Embecta by 224.0% in the first quarter. Jane Street Group LLC now owns 132,688 shares of the company’s stock worth $1,692,000 after buying an additional 91,729 shares during the period. Institutional investors and hedge funds own 93.83% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on EMBC shares. Weiss Ratings downgraded Embecta from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, August 3rd. Bank of America reduced their price objective on Embecta from $11.00 to $3.00 and set an “underperform” rating on the stock in a research note on Monday, May 18th. Finally, Zacks Research upgraded Embecta from a “strong sell” rating to a “hold” rating in a report on Friday, July 17th. Three analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average target price of $11.00.

Check Out Our Latest Stock Analysis on EMBC

About Embecta

(Get Free Report)

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.